ArticleBiotechnology letters2026
Development and validation of a novel latex particle-enhanced turbidimetric immunoassay for fecal calprotectin.
Article in Biotechnology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundFecal calprotectin (FCP) is a crucial non-invasive biomarker for diagnosing and monitoring inflammatory bowel disease (IBD). However, the standard enzyme-linked immunosorbent assay (ELISA) is time-consuming and labor-intensive. This study aimed to develop a novel, independent latex particle-enhanced turbidimetric immunoassay (PETIA) suitable for open-channel automated biochemical analyzers, offering a flexible and cost-effective alternative to existing commercial PETIA kits.
methodsRecombinant human S100A8 and S100A9 proteins (the subunits of calprotectin) were expressed in E. coli and purified. Polyclonal antibodies were generated in rabbits by immunization with these proteins. The antibodies were then covalently coupled to carboxylated latex particles (188 nm) to create the PETIA reagent. The assay was validated on an LC-400 specific protein analyzer. Analytical performance-including repeatability, within-lab precision, and interference-was assessed. The method was evaluated using clinical fecal samples (n = 104) and compared with a commercial ELISA kit (BÜHLMANN fCAL).
resultsThe developed PETIA demonstrated a measuring range of 0-1500 µg/g based on a six-point calibration curve (R
conclusionThe PETIA showed strong correlation with the established ELISA for FCP quantification, offering a rapid, automated alternative suitable for high-throughput laboratories. This study, encompassing development from antibody to reagent, supports its translational potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.